Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL)

Inclusion Criteria

• •Adult patient;
• •ECOG performance status 0-2;
• •Patient with melanoma stage IIB or IIC, or any stage III, or stage IV that has been resected or is resectable;
• •Treatment-naïve patient (except for initial excisional biopsy performed for diagnostic purposes);
• •Patient scheduled to receive adjuvant therapy within 12 weeks following surgery, consisting of anti-BRAF and anti-MEK kinase inhibitors or anti-PD-1 monoclonal antibody immunotherapy, in accordance with marketing authorization;
• •Patient with stage IIIB, IIIC, IIID, or IV melanoma with macroscopic lesions (clinically or radiologically detectable) eligible for neoadjuvant therapy, surgery, and adjuvant therapy (according to current recommendations: ESMO and NCCN guidelines, and treatment regimens from the SWOG S1801 and NADINA studies);
• •Biological parameters compatible with the planned treatment;
• •Patient informed and having provided written informed consent.